Italia markets closed

Neumora Therapeutics, Inc. (NMRA)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
9,17-0,14 (-1,50%)
Alla chiusura: 04:00PM EDT
9,17 0,00 (0,00%)
Dopo ore: 04:01PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente9,31
Aperto9,30
Denaro0,00 x 0
Domanda0,00 x 0
Min-Max giorno8,95 - 9,38
Intervallo di 52 settimane8,82 - 21,00
Volume285.744
Media Volume644.777
Capitalizzazione1,463B
Beta (mensile su 5 anni)N/D
Rapporto PE (ttm)N/D
EPS (ttm)-1,59
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A25,25
  • GlobeNewswire

    Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development

    Dr. Lenz brings 20 years of neuroscience drug development expertise, with deep experience implementing successful clinical programs to support the development of novel medicinesWATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Robert Lenz, M.D., Ph.D., as executive vice president, head of research and development. Dr. Lenz is a membe

  • GlobeNewswire

    Neumora Therapeutics Announces Pricing of Initial Public Offering

    WATERTOWN, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (“Neumora”), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the pricing of its initial public offering of 14,710,000 shares of its common stock at a price to the public of $17.00 per share. All of the shares are being offered by Neumora. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable